Ontario's law curbing the cost of generic drugs sparks changes for pharmacies and other Canadian buyers.
作者信息
Silversides Ann
出版信息
CMAJ. 2009 Aug 4;181(3-4):E43-5. doi: 10.1503/cmaj.091155.
Abstract
摘要
相似文献
1
Ontario's law curbing the cost of generic drugs sparks changes for pharmacies and other Canadian buyers.安大略省一项抑制非专利药成本的法律给药店及其他加拿大买家带来了变化。
CMAJ. 2009 Aug 4;181(3-4):E43-5. doi: 10.1503/cmaj.091155.
2
Pharmacies receiving massive rebates from generic drug-makers.从仿制药制造商那里获得巨额回扣的药店。
CMAJ. 2006 Aug 15;175(4):342. doi: 10.1503/cmaj.060904.
3
Ontario's plunging price-caps on generics: deeper dives may drown some drugs.安大略省大幅下调仿制药价格上限：深入探究可能会使一些药物陷入困境。
Open Med. 2011;5(3):e149-52. Epub 2011 Sep 27.
4
Generic drugs: shop around for the best deals.通用药物：多方比较以获取最优惠价格。
Consum Rep. 2006 Nov;71(11):58-9.
5
Cost and price of comparable branded and generic pharmaceuticals.
JAMA. 1986 Nov 14;256(18):2523-30.
6
Entry of new pharmacies in the deregulated Norwegian pharmaceuticals market--consequences for costs and availability.新药店进入放松管制的挪威药品市场——对成本和可及性的影响
Health Policy. 2008 Aug;87(2):258-63. doi: 10.1016/j.healthpol.2007.10.016. Epub 2008 Mar 4.
7
Third-party reimbursement for generic prescription drugs: The prevalence of below-cost reimbursement in an environment of maximum allowable cost-based reimbursement.第三方报销仿制药：在最高限价成本报销环境下，低于成本的报销盛行。
J Am Pharm Assoc (2003). 2018 Jul-Aug;58(4):421-425. doi: 10.1016/j.japh.2018.04.018. Epub 2018 May 31.
8
Dormant Commerce Clause--Extraterritoriality Doctrine--Fourth Circuit Invalidates Maryland Statute Regulating Price Gouging in the Sale Of Generic Drugs.--Association for Accessible Medicines v. Frosh, 887 F.3d 664 (4th Cir. 2018).休眠商业条款——域外效力原则——第四巡回上诉法院判定马里兰州一项规范非专利药品销售中哄抬物价行为的法规无效。——可及药品协会诉弗罗什案，887 F.3d 664（第四巡回上诉法院，2018年）
Harv Law Rev. 2019 Apr;132(6):1748-55.
9
The spread: pilot study of an undocumented source of pharmacy benefit manager revenue.传播：一项关于药品福利管理公司收入未记录来源的试点研究。
J Am Pharm Assoc (2003). 2004 Jan-Feb;44(1):15-21. doi: 10.1331/154434504322713183.
10
The Impact of Price-cap Regulations on Exit by Generic Pharmaceutical Firms.价格上限监管对仿制药公司退出市场的影响。
Med Care. 2016 Sep;54(9):884-90. doi: 10.1097/MLR.0000000000000577.
引用本文的文献
1
Minor ailments, major problems: a critical appraisal of Rafferty et al. (2017).小疾病，大问题：对拉弗蒂等人（2017年）的批判性评价。
Cost Eff Resour Alloc. 2018 Nov 19;16:57. doi: 10.1186/s12962-018-0160-5. eCollection 2018.
2
Generic drugs in Canada: an examination of tiered pricing.加拿大的仿制药：分层定价研究。
CMAJ. 2015 Oct 6;187(14):1033-1034. doi: 10.1503/cmaj.150395. Epub 2015 Jul 13.
3
Cost-control mechanisms in Canadian private drug plans.加拿大私立药品计划中的成本控制机制。
Healthc Policy. 2013 Aug;9(1):35-43.
4
The TSX Gives a Short Course in Health Economics: It's the Prices, Stupid!多伦多证券交易所提供了一堂健康经济学的速成课：关键在于价格，笨蛋！
Healthc Policy. 2010 Nov;6(2):13-23.
Zotero 插件